Free Trial
NASDAQ:EDSA

Edesa Biotech 2/14/2025 Earnings Report

Edesa Biotech logo
$2.49 -0.12 (-4.60%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$2.49 0.00 (0.00%)
As of 10/10/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edesa Biotech EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.17
One Year Ago EPS
-$0.54

Edesa Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Edesa Biotech Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Edesa Biotech's next earnings date is estimated for Friday, December 12, 2025, based on past reporting schedules.

Conference Call Resources

Edesa Biotech Earnings Headlines

Edesa Biotech Launches At-The-Market Offering Program
EDSA: EB06 Manufacturing to be Completed by End of 2025…
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Edesa Biotech Posts Narrower Loss in Q3
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
See More Edesa Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email.

About Edesa Biotech

Edesa Biotech (NASDAQ:EDSA) is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials. In parallel, the company is developing therapeutic vaccine constructs to address oncoviruses and tumor-associated antigens, as well as prophylactic immunizations for broader viral threats. Edesa’s integrated research facilities in Cambridge, Massachusetts support discovery, preclinical evaluation and process development in collaboration with academic and contract manufacturing partners.

Headquartered in Cambridge, Edesa Biotech was founded by a team of immunologists and industry veterans. The company serves global markets through strategic alliances in North America, Europe and Asia. Under the leadership of CEO Steven M. Powell, PhD, Edesa is positioned to advance its pipeline toward late-stage clinical trials and to establish a differentiated platform for both infectious disease prevention and cancer immunotherapy.

View Edesa Biotech Profile

More Earnings Resources from MarketBeat